PT-141 for Women — How Bremelanotide Increases Female Libido
PT-141 for Women: How Bremelanotide Treats Low Libido and HSDD
Reviewed by the CoreSup Research Team · Based on FDA-approved Vyleesi label, RECONNECT Phase 3 trial data (1,247 women), and peer-reviewed women's health literature · Updated March 2026
PT-141's story is fundamentally a women's health story. While most discussions of bremelanotide focus on its role in male sexual dysfunction, the compound achieved its FDA approval — and its scientific legitimacy — through a rigorous, multi-year clinical programme specifically designed to address one of the most prevalent and least-treated female sexual health conditions: hypoactive sexual desire disorder (HSDD).
On June 21, 2019, the FDA approved bremelanotide as Vyleesi — a 1.75 mg subcutaneous auto-injector — specifically for premenopausal women with acquired, generalised HSDD. It was the first FDA-approved as-needed treatment for this condition in history. That's not marketing language. It's a regulatory milestone that took nearly two decades of development, a series of abandoned attempts at earlier melanocortin compounds, and two Phase 3 randomised controlled trials to achieve.
This guide explains what HSDD is, what the RECONNECT trial data actually showed, how PT-141 differs from the other FDA-approved HSDD treatment (Addyi/flibanserin), and what women in UAE need to know about dosage, side effects, and research access.
TL;DR: PT-141 (bremelanotide) was FDA-approved in 2019 as Vyleesi for HSDD in premenopausal women — the first as-needed treatment for this condition. RECONNECT Phase 3 trials (1,247 women, 24 weeks) showed statistically significant improvements in desire scores and distress reduction vs placebo (P<0.001). The approved dose is 1.75 mg subcutaneous injection, 45 min before activity, max 8×/month. Nausea affects 40% but is transient. Works by activating MC4R brain receptors — not hormonal, not daily.
What Is HSDD and How Many Women Does It Affect?
Hypoactive sexual desire disorder is defined as persistently low or absent sexual desire that causes significant personal distress. The critical component is the distress criterion — a woman can have lower desire than average without having HSDD if it doesn't cause her distress. When it does cause distress, when it represents a change from her normal baseline, and when it's not explained by another medical condition or medication side effect, the HSDD diagnosis applies.
Prevalence estimates for HSDD in premenopausal women typically range from 8–10% globally. It's more common than most people realise, partly because it's dramatically underreported and undertreated. In the UAE and GCC, cultural barriers to discussing sexual health concerns with physicians likely mean the prevalence is practically higher than reported rates suggest.
What the RECONNECT Trials Actually Showed for Women
The RECONNECT programme consisted of two identical 24-week, randomised, double-blind, placebo-controlled trials conducted at multiple sites, enrolling 1,247 premenopausal women with HSDD. The primary efficacy endpoints were changes from baseline in: (1) the Female Sexual Function Index Desire domain (FSFI-D) score, and (2) the Female Sexual Distress Scale — Arousal, Desire, Orgasm subscale (FSDS-DAO).
Both endpoints met statistical significance in both trials (PMC6819021, 2019):
- FSFI-D improvement: +0.35 bremelanotide vs placebo (P<0.001)
- FSDS-DAO distress reduction: −0.33 bremelanotide vs placebo (P<0.001)
- Desire score: ~25% of bremelanotide users showed meaningful improvement vs ~17% placebo
The effect sizes here are modest — a +0.35 improvement on the FSFI-D scale is real but not dramatic. It's important to contextualise this honestly: HSDD has significant psychological, relational, and contextual drivers that no pharmacological intervention fully addresses. What the RECONNECT data shows is that PT-141 produces a real, measurable, statistically significant improvement in desire and distress — not a cure, not a transformation, but a clinically meaningful shift that was sufficient for FDA approval and that the majority of women in the trials found worth continuing despite side effects.
PT-141 vs Addyi (Flibanserin): The Two FDA-Approved HSDD Options
Addyi (flibanserin), approved in 2015, was the first FDA-approved treatment for HSDD. PT-141 (Vyleesi) was the second, in 2019. They're very different compounds.
| Feature | PT-141 / Vyleesi | Addyi (Flibanserin) |
|---|---|---|
| Mechanism | MC3R/MC4R agonist — melanocortin pathway | 5-HT1A agonist / 5-HT2A antagonist — serotonin pathway |
| Administration | Subcutaneous injection (as-needed) | Daily oral tablet (100 mg at bedtime) |
| When to use | 45 min before anticipated activity | Daily — not as-needed |
| Time to effect | 45–60 minutes | Weeks of consistent use required |
| Alcohol interaction | Avoid concurrent use | Absolute contraindication — dangerous hypotension |
| Main side effect | Nausea (40%) | Somnolence, dizziness, nausea |
| Effect size | Statistically significant in two RCTs | Modest — debated at FDA approval |
For women who prefer on-demand treatment over daily medication and don't want to manage Addyi's strict alcohol contraindication, PT-141 is typically the more practical choice. For women who prefer oral tablets and consistent daily support, Addyi remains an option where available with prescription access. Neither is available without prescription access in the UAE — PT-141 is sourced here as a research compound through suppliers like CoreSup.
PT-141 Dosage for Women: What the FDA Label Specifies
The approved dose is 1.75 mg subcutaneous injection, administered at least 45 minutes before anticipated sexual activity. The injection site is the abdomen or outer thigh. Maximum frequency: one dose per 24 hours, no more than 8 doses per month.
Women experiencing significant nausea should start at 1.0–1.25 mg for the first 2–3 uses before moving to the full dose. Many find nausea diminishes substantially after the first few uses as MC1R desensitisation occurs. No weight-based dose adjustment is specified in the FDA label — the 1.75 mg flat dose applies regardless of body weight.
The evening injection strategy is particularly well-suited for women using PT-141: injecting 3–4 hours before sleep means any nausea (which peaks within 60 minutes) passes during sleep, and the 6–12 hour duration of effect extends through the following morning. This turns the timing challenge into a practical advantage for many users.
For complete dosing and reconstitution guidance, see the PT-141 dosage guide. For the full mechanism overview, see the PT-141 complete guide.
Frequently Asked Questions: PT-141 for Women
Is PT-141 FDA-approved for women?
Yes. PT-141 (bremelanotide) was FDA-approved June 21, 2019 as Vyleesi (1.75 mg subcutaneous) for premenopausal women with acquired, generalised HSDD — the first FDA-approved as-needed HSDD treatment. The approval was based on RECONNECT Phase 3 trials across 1,247 women showing statistically significant improvements in desire scores and distress reduction (P<0.001).
What is HSDD and how common is it?
HSDD is persistently low or absent sexual desire that causes significant personal distress — not just lower desire, but distress about that lower desire. It affects an estimated 8–10% of premenopausal women globally. PT-141 was specifically approved for the acquired, generalised subtype: HSDD that developed after a period of normal desire and isn't situational or relationship-specific.
What PT-141 dosage is right for women?
The FDA-approved dose is 1.75 mg subcutaneous injection, at least 45 minutes before activity. Start at 1–1.25 mg if nausea-sensitive and titrate up. Maximum 8 doses per month. No weight adjustment needed. Evening injection (3–4 hrs before sleep) is the most effective strategy for managing nausea while maintaining a full activity window.
How does PT-141 compare to Addyi for women?
PT-141 is as-needed (inject 45 min before activity, works within hours). Addyi requires daily oral dosing for weeks before effect and has strict alcohol contraindication. PT-141 suits women preferring on-demand treatment; Addyi suits those who prefer daily medication. PT-141's effect size was consistent across two RCTs; Addyi's was more debated at approval.
Can postmenopausal women use PT-141?
The FDA approval is for premenopausal women. RECONNECT enrolled only premenopausal participants, so formal efficacy data in postmenopausal women is limited. PT-141's MC4R mechanism is not oestrogen-dependent — the relevant brain receptors exist post-menopause. Some clinicians extend its use off-label, but this is outside the approved indication. Consult a physician.
Research PT-141 for Women in UAE
CoreSup supplies research-grade bremelanotide (PT-141) with third-party HPLC documentation. Delivered to Dubai, Abu Dhabi, and all Emirates.
Browse PT-141 at CoreSup →
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Shop Featured Products
Related Products
Written by Amir Arsalan
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: March 2026 · About Core Sup
